Yijun Huang* and Hong Zhang Pages 120 - 128 ( 9 )
Background: T cell activation via the blockade of PD-1 pathway has been recognized as an emerging drug target for cancer immunotherapy which provides a rationale for clinical trials in cancer patients. The recent breakthrough approvals of T cell checkpoint inhibitors targeting PD-1 pathway boost the era of immuno-oncology drugs.
Methods: The progress of PD-1 checkpoint inhibitor as a single agent in the field of immuno-oncology is reviewed. Antibodies targting PD-1 and PD-L1 with regulatroy approvals are discussed with the current coverage of indications. Other candidates in clinical investigations are also summarized.
Results: Monoclonal antibodies that block protein-protein interactions between PD-1 and its ligand have shown the promise for the treatment of a variety of cancer types. The fast growing family of PD-1 checkpoint inhibitors been observed both in regulatroy approvals and clinical investigations.
Conclusion: The potential use of PD-1 checkpoint inhibitor alone or in combination with other agents is substantial, and will further reveal the important role of PD-1 pathway in immunomodulation and disease control.
PD-1, PD-L1, checkpoint inhibitors, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab
WuXi AppTec Inc., 4701 League Island Boulevard, Philadelphia, PA 19112, DePuy Synthes, 1302 Wrights Lane East, West Chester, PA 19380